Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HOTH
- Price
- 1.21
- Stock movement up
- +0.04 (3.20%)
- Company name
- Hoth Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 17.10M
- Ent value
- 9.89M
- Price/Sales
- 287.28
- Price/Book
- 2.28
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.05%
- 1 year return
- 70.91%
- 3 year return
- -51.42%
- 5 year return
- -54.65%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
HOTH does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 287.28 |
| Price to Book | 2.28 |
| EV to Sales | 166.19 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 13.26M |
| EPS (TTM) | -1.09 |
| FCF per share (TTM) | -1.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 59.54K |
| Gross profit (TTM) | 29.77K |
| Operating income (TTM) | -7.53M |
| Net income (TTM) | -7.51M |
| EPS (TTM) | -1.09 |
| EPS (1y forward) | -0.43 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 50.00% |
| Operating margin (TTM) | -12647.51% |
| Profit margin (TTM) | -12609.72% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 8.02M |
| Net receivables | 0.00 |
| Total current assets | 8.24M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 59.70K |
| Total assets | 8.31M |
| Accounts payable | 504.81K |
| Short/Current long term debt | 33.81K |
| Total current liabilities | 810.32K |
| Total liabilities | 813.03K |
| Shareholder's equity | 7.49M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.02M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -8.02M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -100.18% |
| Return on Assets | -90.37% |
| Return on Invested Capital | -99.76% |
| Cash Return on Invested Capital | -106.59% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.27 |
| Daily high | 1.30 |
| Daily low | 1.23 |
| Daily Volume | 163K |
| All-time high | 202.50 |
| 1y analyst estimate | 5.00 |
| Beta | 0.67 |
| EPS (TTM) | -1.09 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| HOTH | S&P500 | |
| Current price drop from All-time high | -99.36% | -1.46% |
| Highest price drop | -99.71% | -56.47% |
| Date of highest drop | 7 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -81.57% | -10.99% |
| Avg time to new high | 409 days | 12 days |
| Max time to new high | 1559 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
17.10M
Marketcap category
Small-cap
Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Employees
2
Website
Investor relations
-
SEC filings
CEO
Robbie Knie
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page